Posts

Prostate Cancer - San Bernardino CA (Clinical Trial # 58871)

Prostate Cancer - San Bernardino CA (Clinical Trial # 58871) clinicalconnection.com Clinical Trial 58871 share with a friend San Bernardino , CA 92404 Summary: This is a clinical research study of an investigational medication, EPI-7386, for patients with metastatic castrate resistant prostate cancer.  The investigational medication will be given together with enzalutamide in order to test the effectiveness of the combination of EPI-7386 and enzalutamide versus enzalutamide alone.  Partial Criteria: Have rising PSA levels Be
Post a Comment
Read more

Pfizer's Cancer Drug Combo Improves Overall Survival in Late-stage Study

Image
Pfizer's Cancer Drug Combo Improves Overall Survival in Late-stage Study medscape.com Short Summary for Patients Here's a summary tailored for patients with metastatic castration-resistant prostate cancer (mCRPC): 1. New Treatment Option:    - Pfizer has developed a new combination treatment for mCRPC.    - It combines two drugs: TALZENNA (talazoparib) and XTANDI (enzalutamide). 2. Who It's For:    - This treatment is for men with mCRPC, which means prostate cancer that:      - Has spread to other parts of the body      - No longer responds to hormone therapy or surgery to lower testosterone 3. How It Works:    - TALZENNA is a type of drug called a PARP inhibitor.    - XTANDI blocks the effects of male hormones on prostate cancer.    - Together, they attack cancer in two different ways. 4. Effectiveness:    - In clinical trials, this combination showed significant benefits:      - It helped patients live longer overall.      - It slowed dow
Post a Comment
Read more

Prognostic value of PSMA PET in predicting long‐term biochemical control following curative intent treatment for prostate cancer - Ades - Journal of Medical Imaging and Radiation Oncology - Wiley Online Library

Image
Summary of Multiple Sources on Prognostic Impact of PSMA PET/CT for Prostate Cancer Care PSMA PET/CT scans can help predict post-treatment progress of prostate cancer in several ways: 1. Predicting biochemical recurrence and survival: - Patients with positive nodes (miN1) on PSMA PET have significantly shorter time to biochemical failure compared to node-negative patients after radical prostatectomy. - The number of PSMA-avid nodes is predictive of biochemical progression-free survival, with two or more nodes associated with worse outcomes. - PSMA PET-derived volumetric metrics like whole-body PSMA tumor volume (wbPSMA-TV) and total lesion PSMA (wbPSMA-TL) correlate with serum PSA, tumor Gleason score, and shorter progression-free survival. 2. Guiding salvage therapy decisions: - PSMA PET can localize recurrence to the prostate bed, pelvic lymph nodes, or distant sites, which impacts salvage therapy approaches. - Patients with negative PSMA PET prior to salvage radiotherapy have better
Post a Comment
Read more